Biomind Labs Inc. (BMNDF)

OTCMKTS · Delayed Price · Currency is USD
0.1200
0.00 (0.00%)
May 5, 2026, 4:00 PM EST
Market Cap9.31M
Revenue (ttm)n/a
Net Income-850.41K
EPS-0.01
Shares Out77.57M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,210
Average Volume2,430
Open0.1200
Previous Close0.1200
Day's Range0.1200 - 0.1200
52-Week Range0.0110 - 0.1305
Beta7.50
RSI47.68
Earnings DateMay 14, 2026

About Biomind Labs

Biomind Labs Inc., a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. The company is developing BMND01, which is in Phase II clinical trials for use in the treatment of depression; BMND08, a 5-Metoxi-N,N-dimethyltryptamine based formulation that is in Phase II clinical trials for treatment of depression and anxiety in patients with Alzheimer’s-type cognitive impairment; BMND06 is in Phase I clinical trial for treatment of... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Alejandro Antalich
Country Canada
Stock Exchange OTCMKTS
Ticker Symbol BMNDF
Full Company Profile

Financial Performance

Financial Statements